Mustang Bio, Inc. (MBIO)
NASDAQ: MBIO · Real-Time Price · USD
1.470
-0.060 (-3.92%)
At close: Aug 1, 2025, 4:00 PM
1.480
+0.010 (0.68%)
After-hours: Aug 1, 2025, 7:57 PM EDT

Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases.

It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134.

The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Mustang Bio, Inc.
Mustang Bio logo
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees6
CEOManuel Litchman

Contact Details

Address:
95 Sawyer Road, Suite 110
Waltham, Massachusetts 02453
United States
Phone781 652 4500
Websitemustangbio.com

Stock Details

Ticker SymbolMBIO
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001680048
CUSIP Number62818Q302
ISIN NumberUS62818Q3020
Employer ID47-3828760
SIC Code2834

Key Executives

NamePosition
Dr. Manuel Litchman M.D.President, Chief Executive Officer, Interim Chief Financial Officer and Director
Michael S. Weiss Esq., J.D.Executive Chairman
Peter CarneyController and Interim Chief Accounting Officer
Greg Furrow M.S.Chief Quality Officer
Robyn M. HunterCorporate Secretary

Latest SEC Filings

DateTypeTitle
Jul 9, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 14, 202510-QQuarterly Report
May 9, 2025SCHEDULE 13G/AFiling
Apr 11, 2025EFFECTNotice of Effectiveness
Apr 4, 2025POS AMPost-Effective amendments for registration statement
Apr 2, 2025SCHEDULE 13D/AFiling
Apr 1, 2025POS EXFiling
Apr 1, 2025424B3Prospectus
Mar 28, 202510-KAnnual Report